Tevogen Bio Holdings (TVGN) Accumulated Expenses (2023 - 2026)

Tevogen Bio Holdings has reported Accumulated Expenses for 4 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 37.42% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 37.42% YoY), and the FY2025 full-year result was $1.5 million, down 12.43% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.2 million, down from $1.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $2.0 million in Q1 2025, with the low at $1.1 million in Q4 2023.
• Historically, Accumulated Expenses has averaged $1.5 million across 4 years, with a median of $1.5 million in 2024.
• Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 56.18% — and 2026, when it sank 37.42%.
• Tevogen Bio Holdings' Accumulated Expenses stood at $1.1 million in 2023, then jumped by 56.18% to $1.7 million in 2024, then fell by 12.43% to $1.5 million in 2025, then decreased by 17.23% to $1.2 million in 2026.
• The last three Accumulated Expenses figures came in at $1.2 million (Q1 2026), $1.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.